Tumour endothelial cells (TEC) display a distinct and angiogenic phenotype. They also permit trafficking of anti-tumour CD8+ T-lymphocytes into tumour stroma. I aimed to develop and validate an isolation technique and in vitro model of primary human colorectal TEC, characterize the TEC phenotype, and investigate intratumoural micro-environmental signals regulating CD8+ T-cell recruitment by TEC. Flow cytometry, ELISA and QPCR revealed CD31, VWF, CD105, VEGFR’s, VE-Cadherin, CD13 and tumour specific marker TEM8 expression by colorectal TEC. TEC and tumour associated fibroblast (TAFB) produced higher concentrations of IL-6 and CCL2/MCP-1. Static and flow-based assays, demonstrated increased CD8+ T-cell adhesion by TEC and adhesion was augmented after conditioning with CRC derived TAFB supernatant. IL-6 and CCL2/MCP-1 blockade supressed CD8 T-cell adhesion. Endothelin-1 (ET1) was produced by TAFB and Endothelin Receptor B (ETB) was preferentially expressed by CRC endothelium, blockade of which, resulted in significantly increased ICAM-1 expression and CD8+ T-cell adhesion to TEC. My validated in vitro TEC model confirms that CRC TEC has a unique phenotype influenced by the tumour microenvironment and that ETB inhibition may facilitate increased recruitment of CD8+ T-lymphocytes into the tumour stroma. This commands further investigation with the aim of developing an anti-cancer therapy in CRC.